Navigation Links
Pfenex Reports Second Quarter 2014 Results and Provides Business Update
Date:8/29/2014

our government contracts, offset in part by a decrease in the protein production service work. 
  • Cost of revenue was $2.5 million in the second quarter of 2014 compared to $1.3 million in the second quarter of 2013.  The increase in cost of revenue was due primarily to the increased development costs for our proprietary novel vaccine programs which are funded by various government agencies.
  • Research and development expenses were $0.9 million for the second quarter of 2014 compared to $1.3 million in the second quarter of 2013.  The decrease in research and development expenses was due in part to an increase in development activity by our partner, Stelis, and resulting decrease in activity by Pfenex, of PF530, as well as manufacturing activity and purchase of comparator material for our product candidate, PF582, phase 1b/2a trial in the year ago period.  We expect research and development expense to increase as we advance our lead candidates and pipeline products.
  • Selling, general and administrative expenses were $2.0 million in the second quarter of 2014 compared to $1.7 million in the second quarter of 2013.  The increase in selling, general and administrative expenses was due to an increase in audit and consulting fees.  We expect selling, general and administrative expenses to increase for activities associated with operating as a public company. 
  • Not including the proceeds from our initial public offering and the exercise of the underwriters' option to purchase additional shares, cash, cash equivalents and short-term investments, excluding restricted cash, was $3.9 million as of June 30, 2014, compared to $5.2 million as of December 31, 2013.  As of June 30, 2014 we had $3.8 million drawn under our $3.9 million revolving credit facility and $4.0 million of restricted cash as collateral for the credit facility.
  • Forward-Looking StatementThis press release contains forward-lo
    '/>"/>

    SOURCE Pfenex Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Pfenex Inc. Awards Glide Pharma Development Contract for a Solid Formulation of Recombinant Anthrax Vaccine
    2. Pfenex Inc. Awards Paragon Bioservices a Contract for cGMP Manufacturing of its Recombinant Protective Antigen (rPA), for Phase 1 Clinical Trial of its Anthrax Vaccine
    3. Pfenex Awarded Contract For Development Of Next Generation rPA-Based Anthrax Vaccine
    4. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    5. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    6. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    7. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    8. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    9. Pharmasset Reports Fiscal Year End 2011 Financial Results
    10. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    11. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/1/2015)... SILVER SPRING, Md. and RESEARCH TRIANGLE ... Corporation (NASDAQ: UTHR ) announced today that Roger ... Therapeutics, will provide an overview and update on the company,s ... Care Conference in Boston, Massachusetts . ... 2015, at 3:30 PM Eastern Time, and can be accessed ...
    (Date:4/30/2015)... , April 30, 2015  Roka Bioscience, Inc. ... on providing advanced testing solutions for the detection of ... for the first quarter of 2015 on May 7, ... Roka Bioscience will also host a conference call ... to discuss its first quarter financial results. During the ...
    (Date:4/30/2015)... (PRWEB) April 30, 2015 Cytokinetics, Incorporated (Nasdaq: ... quarter of 2015 were $4.4 million, compared to $8.0 million ... for the first quarter was $8.9 million, or $0.23 per ... loss for the same period in 2014, of $8.7 million, ... March 31, 2015, cash, cash equivalents and investments totaled $117.5 ...
    (Date:4/30/2015)... Nitto Avecia, a leading biotechnology manufacturer and ... production capability to serve biotechnology pharmaceutical clients. A ... continues to drive Nitto Avecia to enhance synthesis ... , In Fall 2014, Nitto Avecia first ... its Milford, MA facility, which is recognized as ...
    Breaking Biology Technology:Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2
    ... , BRISBANE, Calif., Oct. 29 InterMune, Inc. (Nasdaq: ... 2009 financial results on Thursday, November 5, 2009 at 4:00 ... will be hosted by InterMune at 4:30 p.m. Eastern time ... 888-799-0528 (U.S.) or 973-200-3372 (international), conference ID# 37626791. To ...
    ... SOLANA BEACH, Calif. & HAMILTON, New Zealand, Oct. 29 ... products for DNA extraction and other life sciences applications, ... with VERITAS Japan to distribute ZyGEM,s DNA extraction products ... the latest in a series of recent major distribution ...
    ... Calif., Oct. 29 NeurogesX, Inc. (Nasdaq: NGSX ... novel pain management therapies, announced today that Anthony DiTonno, ... at two upcoming conferences in New York City: the ... held November 3-4, 2009 and the Lazard Capital Markets ...
    Cached Biology Technology:InterMune to Release Third Quarter Financial Results on November 5 2ZyGEM Strengthens its Worldwide Presence With New Distribution Agreement for Japan 2ZyGEM Strengthens its Worldwide Presence With New Distribution Agreement for Japan 3ZyGEM Strengthens its Worldwide Presence With New Distribution Agreement for Japan 4NeurogesX to Present at Two November Conferences 2NeurogesX to Present at Two November Conferences 3
    (Date:4/14/2015)... Conn. , April 14, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... been nominated for the 2015 New York Design Awards ... The Design100, New York City Design Awards are part ... based on over 2,500 ratings from the marketplace, industry ...
    (Date:4/8/2015)... 2015  Infinisource, a leading provider of SaaS-based Human ... a leading supplier of biometric identification and security ... most advanced biometrically-enabled time clock, the companies announced ... is setting a bold, new standard for the ... small and mid-size employer. When connected to the ...
    (Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... for its touch fingerprint sensor FPC1025 from the distributor ... Deliveries will commence during Q2 2015 although the major ... 2015. The sensors will be used by smartphone manufacturers ... of 110 MSEK is included in the communicated revenue ...
    Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
    ... of bacterial communication may have been found. Although they ... about what,s going on in their neighborhood and communicate with ... their surrounding environment. Even though there are millions of different ... world around them, Duke University bioengineers believe they have found ...
    ... on detecting short, repetitive DNA segments in the genome ... repeats. "With this method we are able to identify ... Furthermore, we can show how new pathogenic variants develop," ... have now been published in the current issue of ...
    ... mothers suggests that a group of common environmental contaminants ... consumer products including everyday personal care items, may contribute ... Researchers at the University of Michigan School of ... on average, up to three times the phthalate level ...
    Cached Biology News:Finding the constant in bacterial communication 2Finding the constant in bacterial communication 3The tiny difference in the genes of bacteria 2Chemicals in common consumer products may play a role in pre-term births 2
    Mouse polyclonal antibody to QPRT - quinolinate phosphoribosyltransferase (nicotinate-nucleotide pyrophosphorylase (carboxylating))...
    ... Optimization Kits without ammonium sulfate are compatible ... such as Taq and AmpliThem™™ DNA polymerases. ... PCR systems in one experiment by adding ... into the PreMixes supplied with the kit. ...
    Application: for RNase- decontamination , Registered Trademark of Ambion. ,Special grade: for molecular biology Density: 1.00 g/mL (20 C) Suitab tst: RNase decontamination in accordance...
    ... A cleaning agent for removing ... countertops, and pipettors. It ... RNase contamination from microcentrifuge tubes ... ,RNase Zap (R) ...
    Biology Products: